Compare the Efficacy of Levocetirizine to Montelukast in Reducing Symptoms of SAR in Sensitive Subjects Exposed to Ragweed Pollen
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00315523|
Recruitment Status : Completed
First Posted : April 18, 2006
Last Update Posted : December 16, 2013
|Condition or disease||Intervention/treatment||Phase|
|Rhinitis, Allergic, Seasonal||Drug: Levocetirizine||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||403 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Double-blind, 3 Parallel Randomized Groups, Therapeutic Confirmatory. Clinical Trial to Compare the Efficacy of Levocetirizine 5 mg and Montelukast 10 mg to Placebo in Reducing SAR Symptoms in Ragweed Sensitive Subjects in an EEC.|
|Study Start Date :||July 2006|
|Actual Primary Completion Date :||October 2006|
|Actual Study Completion Date :||October 2006|
- Compare efficacy of Levocetirizine 5 mg to montelukast 10 mg as measured by the mean change from baseline of major symptoms related to SAR in ragweed sensitive subjects.
- Reduction in other SAR symptoms at different time points; Safety .
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00315523
|Mississauga, Ontario, Canada|
|Study Director:||UCB Clinical Trial Call Center||UCB Pharma|